Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is designed to allow existing investigators continued access to the AeroForm Tissue Expander to treat patients while AirXpanders completes a marketing application and during the review process by FDA.
This is a prospective, multi-center, single arm, open-label, continued access clinical study. Subjects who meet the inclusion criteria and agree to participate in the study will be enrolled and implanted with the investigational AeroForm Tissue Expander. If the subject is having a bilateral procedure, the AeroForm expander will be implanted in each side. Subjects will be followed until the first post-operative visit after explant of the tissue expander(s) and exchange for permanent implant(s).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| AeroForm Tissue Expander | Experimental | AeroForm Tissue Expansion inflation with carbon dioxide by remote control |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AeroForm Tissue Expander | Device | The AeroForm Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Breasts With Successful Tissue Expansion With Exchange to a Permanent Breast Implant Unless Exchange is Precluded by a Non-device Related Event | The primary endpoint is analyzed per breast. Breasts in which the expander is removed and/or replaced due to a device related adverse event or a device malfunction are counted as failures. | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Breast With Successful Tissue Expansion With Exchange to Permanent Implant Including All Breasts in the Per Protocol Cohort. | Secondary analysis is repeated including all breasts in the PP cohort (including non-device related failures). The Treatment Success Rate by breast, based on the Per Protocol cohort, including all cause failures, is 95.2% (80/84). One subject (2 breasts) are not included in the analyses due to not completing the second stage surgery and withdrawal of consent. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Daniel Jacobs, M.D. | AirXpanders Chief Medical Officer | Study Chair |
| Jeffrey Ascherman, M.D. | Columbia University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Marin General Hospital | Greenbrae | California | 94904 | United States | ||
| Good Samaritan Hospital, San Jose |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 31881599 | Derived | Ascherman JA, Zeidler K, Morrison KA, Appel J, Castle J, Chun Y, Colwell A, Mohebali K, Stokes T, Sudarsky L. Results of XPAND II: A Multicenter, Prospective, Continued-Access Clinical Trial Using the AeroForm Tissue Expander for Two-Stage Breast Reconstruction. Plast Reconstr Surg. 2020 Jan;145(1):21e-29e. doi: 10.1097/PRS.0000000000006395. |
Not provided
Not provided
Not provided
This study recruited women who were planning to have immediate or delayed breast reconstruction (unilateral or bilateral) post-mastectomy and required tissue expansion to develop tissue coverage for placement of standard breast implant(s). Subjects were identified from the medical practice of the participating investigators.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | AeroForm Tissue Expander | AeroForm Tissue Expansion inflation with carbon dioxide gas by remote control AeroForm Tissue Expander: The AeroForm Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide gas from an internal reservoir to fill and inflate the expander. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
50 Subjects treated under protocol
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | AeroForm Tissue Expander | AeroForm Tissue Expansion inflation with carbon dioxide gas by remote control AeroForm Tissue Expander: The AeroForm Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Breasts With Successful Tissue Expansion With Exchange to a Permanent Breast Implant Unless Exchange is Precluded by a Non-device Related Event | The primary endpoint is analyzed per breast. Breasts in which the expander is removed and/or replaced due to a device related adverse event or a device malfunction are counted as failures. |
| Posted | Count of Units | breasts | 6 months | breasts | breasts |
|
1 year
The safety of the device is evaluated by:
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | AeroForm Tissue Expander | AeroForm Tissue Expansion inflation with carbon dioxide gas by remote control AeroForm Tissue Expander: The AeroForm Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide gas from an internal reservoir to fill and inflate the expander. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| cellulitis | Reproductive system and breast disorders | MedDRA (18.0) | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| erythema | Skin and subcutaneous tissue disorders | MedDRA (18.0) | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Director of Clinical Affairs | AirXpanders | 650-390-9000 | kkelley@airxpanders.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Jun 30, 2015 | Aug 7, 2018 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 6 months |
| San Jose |
| California |
| 95008 |
| United States |
| Broward Health Medical Center | Fort Lauderdale | Florida | 33316 | United States |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | United States |
| Faulkner Hospital | Boston | Massachusetts | 02130 | United States |
| University of Massachusetts Memorial Medical Center | Worcester | Massachusetts | 01605 | United States |
| Columbia University | New York | New York | 10032-3713 | United States |
| Presbyterian Medical Center | Charlotte | North Carolina | 28207 | United States |
| Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Body Mass Index | Mean | Standard Deviation | lbs/in^2 |
|
|
|
|
| Secondary | Number of Breast With Successful Tissue Expansion With Exchange to Permanent Implant Including All Breasts in the Per Protocol Cohort. | Secondary analysis is repeated including all breasts in the PP cohort (including non-device related failures). The Treatment Success Rate by breast, based on the Per Protocol cohort, including all cause failures, is 95.2% (80/84). One subject (2 breasts) are not included in the analyses due to not completing the second stage surgery and withdrawal of consent. | Analysis population includes all treated breasts with the exception of 2 breasts that were not exchanged at the time of study completion (subject withdrew from study) | Posted | Count of Units | breasts | 6 months | breasts | breasts |
|
|
|
|
| 0 |
| 50 |
| 11 |
| 50 |
| 8 |
| 50 |
| wound dehiscence | Reproductive system and breast disorders | MedDRA (18.0) | Systematic Assessment |
|
| hematoma | Reproductive system and breast disorders | MedDRA (18.0) | Systematic Assessment |
|
| seroma | Reproductive system and breast disorders | MedDRA (18.0) | Systematic Assessment |
|
| neutropenic fever, weakness | Immune system disorders | MedDRA (18.0) | Systematic Assessment |
|
| inflammation (red breast syndrome) | Reproductive system and breast disorders | MedDRA (18.0) | Systematic Assessment |
|
| urinary tract infection | Renal and urinary disorders | MedDRA (18.0) | Systematic Assessment |
|
| seroma | Reproductive system and breast disorders | MedDRA (18.0) | Systematic Assessment |
|
Not provided
Not provided
| D017437 |
| Skin and Connective Tissue Diseases |